A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Clinical trial NCT05995353 · RECRUITING

Trial details

NCT number: NCT05995353
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Crohn's Disease

Start date: 2023-12-11
Primary completion: 2029-04-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.